Literature DB >> 15290661

Fecal excretion of human deoxyribonucleic acid as an index of inflammatory activity in ulcerative colitis.

Francesc Casellas1, Maria Antolín, Encarnación Varela, Ana García-Lafuente, Francisco Guarner, Natalia Borruel, José Ramón Armengol Miró, Juan-Ramón Malagelada.   

Abstract

BACKGROUND & AIMS: Several indices evaluate disease activity in ulcerative colitis, but most have drawbacks to their application (invasiveness, complexity, or lack of specificity), and discrepancies between them are frequent. Assuming that desquamation of epithelial and inflammatory cells increases in damaged colonic mucosa, we hypothesized that fecal excretion of human DNA is an index of mucosal inflammation and damage. The aim of our study was to determine whether excretion of human DNA is useful in the evaluation of disease activity in ulcerative colitis.
METHODS: Thirty-one controls and 36 ulcerative colitis patients were included. Ulcerative colitis patients and controls underwent colonoscopic examination after preparation by gut lavage with polyethylene-glycol electrolyte solution. In patients, disease activity was established using the clinical index of Rachmilewitz and an endoscopic score. Feces and gut lavage fluid were obtained and DNA levels were measured by quantitative polymerase chain reaction of the human beta-globin gene.
RESULTS: Fecal DNA excretion correlated with the clinical index (r = 0.59, P < 0.05) and the endoscopic score (r = 0.76, P < 0.01). Gut lavage fluid DNA levels also correlated with clinical and endoscopic activity scores (r = 0.41 and 0.51, respectively, P < 0.05). Fecal DNA excretion was significantly higher in patients with endoscopically or clinically active disease than in controls or patients in remission. Fecal DNA excretion discriminates between endoscopically active disease and remission (sensitivity 0.67, specificity 1.00, P < 0.01).
CONCLUSIONS: Excretion of human DNA in feces, as an expression of cellular desquamation, is a novel noninvasive technique to objectively assess disease activity in ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15290661     DOI: 10.1016/s1542-3565(04)00291-5

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  4 in total

1.  Coamplification of eukaryotic DNA with 16S rRNA gene-based PCR primers: possible consequences for population fingerprinting of complex microbial communities.

Authors:  Geert Huys; Tom Vanhoutte; Marie Joossens; Amal S Mahious; Evie De Brandt; Severine Vermeire; Jean Swings
Journal:  Curr Microbiol       Date:  2008-02-27       Impact factor: 2.188

Review 2.  The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease.

Authors:  James D Lewis
Journal:  Gastroenterology       Date:  2011-05       Impact factor: 22.682

3.  Excretion of Host DNA in Feces Is Associated with Risk of Clostridium difficile Infection.

Authors:  Caroline Vincent; Sudeep Mehrotra; Vivian G Loo; Ken Dewar; Amee R Manges
Journal:  J Immunol Res       Date:  2015-05-18       Impact factor: 4.818

Review 4.  Novel Biomarkers and the Future Potential of Biomarkers in Inflammatory Bowel Disease.

Authors:  Gilles Duvoisin; Robert N Lopez; Andrew S Day; Daniel A Lemberg; Richard B Gearry; Steven T Leach
Journal:  Mediators Inflamm       Date:  2017-04-16       Impact factor: 4.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.